Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate, and uses thereof

A solid pharmaceutical composition comprising an effective amount of at least two of the forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate selected from the group consisting of

• crystalline polymorph Form A as an active ingredient characterized by peaks at 4.90, 9.83, and 25.29°2θ±0.1°2θ;
• crystalline polymorph Form B as an active ingredient characterized by peaks at 4.22, 8.51, and 16.95°2θ±0.1°2θ;
• crystalline polymorph Form B′ as an active ingredient that exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 7;
• crystalline Form C as an active ingredient characterized by peaks at 6.9, 10.1 and 22.6°2θ±0.1°2θ;
• crystalline Form D as an active ingredient characterized by peaks at 10.3, 17.8 and 25.2°2θ±0.1°2θ;
• crystalline Form E as an active ingredient characterized by at least three peaks 10.5, 22.9, 23.2 or 24.6°2θ±0.1°2θ;
• and at least one excipient or carrier.

A method for treating hyperuricemia or a disease caused by elevated uric acid levels, comprising administering an effective amount of at least two of the forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate selected from the group consisting of:

• crystalline polymorph Form A as an active ingredient characterized by peaks at 4.90, 9.83 and 25.29°2θ±0.1°2θ;
• crystalline polymorph Form B as an active ingredient characterized by peaks at 4.22, 8.51, and 16.95°2θ±0.1°2θ;
• crystalline polymorph Form B′ as an active ingredient that exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 7;
• crystalline Form C as an active ingredient characterized by peaks at 6.9, 10.1 and 22.6°2θ±0.1°2θ;
• crystalline Form D as an active ingredient characterized by peaks at 10.3, 17.8 and 25.2°2θ±0.1°2θ;
• crystalline Form E as an active ingredient characterized by at least three peaks 10.5, 22.9, 23.2 or 24.6°2θ±0.1°2θ;
• and at least one excipient or carrier.

A method for treating gout, comprising administering an effective amount of at least two of the forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate selected from the group consisting of:

• crystalline polymorph Form A as an active ingredient characterized by peaks at 4.90, 9.83, and 25.29°2θ±0.1°2θ;
• crystalline polymorph Form B as an active ingredient characterized by peaks at 4.22, 8.51, and 16.95°2θ±0.1°2θ;
• crystalline polymorph Form B′ as an active ingredient that exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 7;
• crystalline Form C as an active ingredient characterized by peaks at 6.9, 10.1 and 22.6°2θ±0.1°2θ;
• crystalline Form D as an active ingredient characterized by peaks at 10.3, 17.8 and 25.2°2θ±0.1°2θ;
• crystalline Form E as an active ingredient characterized by at least three peaks 10.5, 22.9, 23.2 or 24.6°2θ±0.1°2θ;
• and at least one excipient or carrier.